Correspondingly, modulating the PPAR pathway was recognized as an attractive therapeutic avenue for treating cardiac remodeling and Pioglitazone, a PPARγ agonist, was shown to attenuate cardiac remodeling and heart failure after experimental myocardial infarction (MI) [10]. Here, PPARG is linked to heart failure.